KEYNOTE-033: Phase 3 study of pembrolizumab versus docetaxel in patients with previously treated non–small-cell lung cancer (NSCLC)

医学 内科学 多西紫杉醇 肿瘤科 彭布罗利珠单抗 非小细胞肺癌 临床研究阶段 肺癌 癌症 化疗 免疫疗法
作者
C.Z. Zhou,Christian Caglevic,Jianying Zhou,B. Wang,K. Wang,Joy Yang Ge,Yueying Zhou,Bilal Piperdi,Z. Ma
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:28: x143-x143 被引量:5
标识
DOI:10.1093/annonc/mdx671.055
摘要

Background: Docetaxel is widely used in China as second-line therapy for advanced NSCLC, with an objective response rate (ORR) of 5%–10% and median progression-free survival (PFS) and overall survival (OS) of ∼3 and ∼7.5 months, respectively. In KEYNOTE-010, treatment with the humanized anti–PD-1 monoclonal antibody pembrolizumab significantly improved OS as second-line or later therapy in patients with advanced NSCLC expressing PD-L1. KEYNOTE-033 is a randomized open-label study comparing the efficacy and safety of pembrolizumab monotherapy with standard-of-care docetaxel monotherapy in patients (majority from China) with previously treated PD-L1–positive NSCLC. Trial design: Eligible patients in this phase 3 study are aged ≥18 years with confirmed stage III/IV or recurrent PD-L1–positive (tumor proportion score [TPS] ≥1%) NSCLC, with disease progression after ≥1 line of platinum-containing doublet therapy. Patients with tumors with EGFR-sensitizing mutations are excluded and those with ALK translocations must have disease progression on both platinum-containing doublet and ALK-directed tyrosine kinase inhibitor therapy. ∼740 eligible patients will be randomized 1:1 to receive pembrolizumab 2 mg/kg Q3W or docetaxel 75 mg/m2 Q3W. Treatment will be administered for 2 years/35 cycles (whichever is later), or until disease progression, intolerable toxicity, or withdrawal of consent. Randomization will be stratified by PD-L1 TPS (≥50% vs < 50%). Tumor response will be evaluated Q9W by RECIST v1.1 by blinded independent central review. Adverse events occurring during the study will be graded using NCI CTCAE v4.0. Primary endpoints are OS and PFS. Secondary endpoints include ORR and duration of response. Patient-reported outcomes are an exploratory objective. Enrollment has been initiated; 52 sites are planned including 25 in mainland China and others in Argentina, Philippines, Taiwan, Thailand, Mexico, Chile and Ukraine. Clinical trial indentification: ClinicalTrials.gov, NCT02864394. Legal entity responsible for the study: This research was supported by Merck & Co., Inc., Kenilworth, NJ, USA Funding: This research was supported by Merck & Co., Inc., Kenilworth, NJ, USA Disclosure: C. Zhou: Lecture honoraria: Eli Lilly, AstraZeneca, Boehringer Ingelheim, Roche, Sanofi Research Funding: Pfizer, Boehringer Ingelheim, C. Caglevic: Speaker: BMS, MSD, Boehringer Ingelheim, Tecnofarma Advisory and Consulting: BMS, MSD, Boehringer Ingelheim, Eli Lilly, AstraZeneca, Bayer Investigator: MSD, BMS, Boehringer Ingelheim, Bayer, Roche, Astra Zeneca, Astellas, Advaxis Acommodation Grants: Boehringer Ingelheim, J. Ge, Y. Zhou: Employment: MSD China, Shanghai, CN, B. Piperdi: Employment: Merck & Co., Inc., Kenilworth, NJ, US All other authors have declared no conflicts of interest.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LEON完成签到,获得积分10
刚刚
a502410600完成签到,获得积分10
刚刚
佟莫言完成签到 ,获得积分10
2秒前
枫庭紫月完成签到 ,获得积分10
2秒前
安详靖柏完成签到,获得积分10
3秒前
现实的秋凌完成签到,获得积分10
3秒前
远方完成签到,获得积分10
4秒前
Chris完成签到 ,获得积分10
4秒前
郝天鑫完成签到,获得积分10
5秒前
5秒前
eyu完成签到,获得积分20
5秒前
YongZhaHFC完成签到,获得积分10
5秒前
5秒前
阳光完成签到,获得积分10
6秒前
6秒前
陈木木完成签到,获得积分10
7秒前
自然雅旋完成签到,获得积分10
7秒前
Nana完成签到 ,获得积分10
7秒前
Sisyphus完成签到,获得积分10
8秒前
武科大完成签到,获得积分10
8秒前
萌萌大头菜完成签到,获得积分10
8秒前
9秒前
siyue完成签到 ,获得积分20
9秒前
狂跳的脉搏完成签到,获得积分10
10秒前
糟糕的修杰完成签到,获得积分10
10秒前
小城故事完成签到,获得积分10
10秒前
11秒前
哈哈哈完成签到,获得积分10
11秒前
迎风完成签到,获得积分10
11秒前
慕雪完成签到,获得积分10
12秒前
brevo完成签到,获得积分10
12秒前
Owen的应助被夏傥采纳,获得10
12秒前
鲤鱼青雪完成签到,获得积分10
12秒前
饱满天空完成签到 ,获得积分10
12秒前
ayayaya发布了新的文献求助10
13秒前
激昂的紫完成签到 ,获得积分10
13秒前
14秒前
hoenglam发布了新的文献求助10
14秒前
Micro9完成签到,获得积分10
14秒前
不停完成签到,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180111
求助须知:如何正确求助?哪些是违规求助? 9570235
关于积分的说明 21809184
捐赠科研通 7776198
什么是DOI,文献DOI怎么找? 3433262
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479039